William J. Foran has been named president and chief executiveofficer of Quadra Logic Technologies Inc. He was previouslypresident and CEO of Cyanamid Canada Inc. Quadra Logic(NASDAQ:QLTIF) of Vancouver, British Columbia, is developingdrugs that are activated by light.
Biogen Inc. of Cambridge, Mass., said John W. Catterall hasresigned as vice president and treasurer. No replacement wasnamed. Biogen (NASDAQ:BGEN) is a broad-basedbiopharmaceutical company.
Arris Pharmaceutical Corp. of South San Francisco, Calif., hasappointed Heinz Gschwend, Ph.D., vice president of chemistryand Richard Tanaka, Ph.D., director of molecular pharmacology.Gschwend was head of Ciba-Geigy Ltd.'s central researchlaboratories. Tanaka had been section head for the cholesterolprogram at Bristol-Myers Squibb Pharmaceutical ResearchInstitute's department of metabolic diseases. Arris focuses onthe development of a structure-based approach to design smallmolecule drugs.
David T. Rovee, Ph.D., has been named vice president ofresearch and development at Organogenesis of Cambridge,Mass. Rovee was vice president of R&D for Johnson & JohnsonPatient Care Inc. Organogenesis (AMEX:ORG) is focused on theproduction of living tissue and organ equivalents.
California Biotechnology Inc. of Mountain View, Calif., hasnamed Dr. Elliott B. Grossbard vice president of medical andregulatory affairs. Grossbard was architect of the clinicaldevelopment strategy for Genentech Inc.'s Activase tissueplasminogen activator (t-PA). Cal Bio also named Dr. Kenneth L.Luskey director of diabetes and obesity. Luskey was associateprofessor at the Center for Diabetes Research at the Universityof Texas Medical Center. Cal Bio (NASDAQ:CBIO) is focused oncardiopulmonary disease, tissue repair and metabolic disorders.
Gail M. Kempler has joined Regeneron Pharmaceuticals Inc. ofTarrytown, N.Y., as its first corporate patent counsel. Kemplerwas associated with the New York law firm of Kenyon &Kenyon. Regeneron (NASDAQ:REGN) is developing treatmentsfor neurodegenerative diseases, peripheral neuropathies andnerve injuries.
DynaGen Inc. of Cambridge, Mass., has appointed Henry E. Blairto its board. Blair is a co-founder and director of Genzyme Corp.DynaGen (NASDAQ:DYGN) is developing diagnostic andtherapeutic products for human and animal health care.
Natural Product Sciences Inc. of Salt Lake City has appointedDr. Timothy Rink to its board. Rink is president and chieftechnical officer of Amylin Corp. Natural Product Sciences isdeveloping products for pharmaceutical and agrichemicalapplications.
(c) 1997 American Health Consultants. All rights reserved.